[Image courtesy of Spectrum Plastics Group]
Polyvinylchloride (PVC) has long been a go-to material for medical device tubing and other healthcare products. But medtech companies need to think twice about its use now that the European Union is cracking down on the use of PVCs containing di(2-ethylhexyl)phthalate (DEHP) plasticizers, which have caused worries over their potential toxicity.
The E.U. is in the process of phasing in an expansion of its Restriction of Hazardous Substances (RoHS) directive and Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) to include medical devices. The situation has medical device companies shifting to alternative formulations of PVC that don’t have DEHP, or even turning to non-PVC options, according to Larry Wallace, senior staff scientist at Spectrum Plastics Group.
Wallace in this webinar will go over the factors you need to consider if you’re switching to an alternative formulation of PVC, including the need to balance cost versus performance. He’ll also go over potential pitfalls to watch out for when moving away from PVCs altogether.
Featured Speakers:
Larry Wallace
Senior Staff Scientist
Spectrum Plastics Group
Chris Newmarker
Managing Editor
Medical Design and Outsourcing
Tell Us What You Think!